Objectives: The worse complication of kidney biopsy is bleeding. Desmopressin acetate (1-deamino-8-D-arginine-vasopressin), a derivative of vasopressin with minimal vasoconstrictor property, has been used successfully in bleeding disorder like von Willebrand disease and hemophilia A. In renal biopsy the most common complication are bleeding. The aim of this study was to evaluate the effect of desmopressin in reducing bleeding complications after percutaneous kidney biopsy particularly in patients with decreased kidney function. Methods: This was a double-blind, randomized; parallel group, placebo-controlled control trail conducted at the Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow, UP, India between January 2019 and January 2023. The institutional ethical committee approved the study protocol. The outcome of the study was to compare the post biopsy bleed among two groups. Results: A total of 203 (placebo = 102, drug=101) native kidney biopsies were performed after receiving desmopressin. Baseline demographical and clinical variable are given in table-1.The incidence of bleeding differences between placebo and drug group were (30, 29.41% vs 16, 15.84 %; P=0.021). The minor bleeding in placebo vs control (14, 13.72% vs 11, 10.89%; P=0.54) and major bleeding (16, 15.68% vs 5, 4.95: P=0.01) were reported. Conclusions: Desmopressin has significant association in native kidney biopsies before 2 hours of desmopressin administration.